SYNERGENE THERAPEUTICS, INC.

Basic Information

SYNERGENE THERAPEUTICS, INC.
9812 Falls Road, Suite 114
Potomac, MD, 20854-3963

Company Profile

n/a

Additional Details

Field Value
DUNS: 072898005
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 3


  1. HHSN261201400038C;SBIR TOPIC 326 DEVELOPMENT OF NOVEL THERAPEUTIC AGENTS THAT TARGET CANCER STEM CELLS;PROJECT TITLE: CROSSING THE BBB AND TARGETING CSCS FOR GBM THERAPY;CONTRACT PERFORMANCE PERIOD 09

    Amount: $222,900.00

    Not Available

    SBIR Phase I 2014 Department of Health and Human Services
  2. TAS::75 0849::TAS- SYNERGENE, INC SBIR PHASE II OPTION PERIOD

    Amount: $498,331.00

    SBIR Phase II to develop a LYOPHILLIZED form of Optimized scL-gad-d complex

    SBIR Phase I 2011 Department of Health and Human Services
  3. A Tumor-Specific Nanoimmunocomplex Markedly Improves MR Imaging

    Amount: $478,857.00

    DESCRIPTION (provided by applicant): The low rate of cure of pancreatic carcinoma is an important health problem. The American Cancer Society estimates that 32,000 Americans will be diagnosed with car ...

    STTR Phase I 2006 Department of Health and Human Services
  4. A Dual Molecular/Tumor Targeting Therapy for PanCa

    Amount: $1,159,666.00

    DESCRIPTION (provided by applicant): Approximately 30,000 people in the United States are diagnosed each year with pancreatic cancer (PanCa). Over 90% of these will die of the disease making PanCa ...

    STTR Phase II 2004 Department of Health and Human Services
  5. Enhancement of Tumor-Targeted Transgene Expression

    Amount: $201,742.00

    DESCRIPTION (provided by applicant): In this application, the long-term goal is the development of an effective tumor-targeting lipoplex for systemic treatment of pancreatic cancer (PanCa), which has ...

    STTR Phase I 2004 Department of Health and Human Services
  6. A Dual Molecular/Targeting Therapy for PanCa

    Amount: $158,980.00

    DESCRIPTION (provided by applicant): Approximately 30,000 people in the United States are diagnosed each year with pancreatic Cancer (PanCa). Over 90% of these will die of the disease making PanCa one ...

    STTR Phase I 2003 Department of Health and Human Services
  7. TARGETING STEALTH LIPOSOME FOR CANCER GENE THERAPY

    Amount: $138,762.00

    Advanced prostate cancer tends to be relatively refractory to standard chemotherapeutic agents, and this chemoresistance correlates with a lack of functional p53. Our preliminary data indicate that ca ...

    STTR Phase I 2002 Department of Health and Human Services
  8. IMMUNOLIPOSOME-MEDIATED GENE THERAPY FOR PROSTATE CANCER

    Amount: $634,660.00

    DESCRIPTION (provided by applicant): Advanced prostate cancer tends to be relatively refractory to standard chemotherapeutic agents and radiation treatment, and this resistance correlates with a lack ...

    STTR Phase II 2002 Department of Health and Human Services
  9. IMMUNOLIPOSOME-MEDIATED GENE THERAPY FOR PROSTATE CANCER

    Amount: $0.00

    DESCRIPTION (provided by applicant): Advanced prostate cancer tends to be relatively refractory to standard chemotherapeutic agents and radiation treatment, and this resistance correlates with a lack ...

    STTR Phase I 2002 Department of Health and Human Services
  10. IMMUNOLIPOSOME MEDIATED GENE THERAPY FOR PROSTATE CANCER

    Amount: $138,625.00

    N/A

    STTR Phase I 1999 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government